Chargement en cours...
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma
Ibrutinib is a Bruton tyrosine kinase inhibitor that is approved by the FDA for the treatment of mantle cell lymphoma and other hematological malignancies. Bruton tyrosine kinases promote platelet aggregation, and, therefore, bleeding is a common side effect of ibrutinib. At least half of patients t...
Enregistré dans:
| Publié dans: | Cureus |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Cureus
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7377008/ https://ncbi.nlm.nih.gov/pubmed/32714681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.8743 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|